Literature DB >> 21969138

Klotho is silenced through promoter hypermethylation in gastric cancer.

Liangjing Wang, Xian Wang, Xiaojia Wang, Pan Jie, Haiqi Lu, Shengjie Zhang, Xiaoying Lin, Emily Ky Lam, Yan Cui, Jun Yu, Hongchuan Jin.   

Abstract

As one of major epigenetic changes to inactivate tumor suppressor genes in human carcinogenesis, promoter hypermethylation was proposed as a marker to define novel tumor suppressor genes and predict the prognosis of cancer patients. In the present study, we found KL (klotho) as a novel tumor suppressor gene silenced through promoter hypermethylation in gastric cancer, the second leading cause of cancer death worldwide. KL expression was downregulated in primary gastric carcinoma tissues (n=22, p<0.05) and all of gastric cancer cells lines examined. Ectopic expression of KL inhibited the growth of gastric cancer cells partially through the induction of apoptosis, demonstrating a tumor suppressive role of KL in gastric cancer. Demethylation with 5-aza-2'-deoxycytidine (Aza) increased KL expression and KL promoter was hypermethylated in gastric cancer cell lines as well as some of primary gastric carcinoma tissues (47/99) but none of normal gastric tissues. Importantly, promoter methylation of KL was significantly associated with the poor outcome of gastric cancer patients (p=0.025, Log-rank test), highlighting the relevance of epigenetic inactivation of KL in gastric carcinogenesis. As a summary, we found that KL is a novel tumor suppressor gene epigenetically inactivated in gastric cancer and promoter methylation of KL could be used to predict the prognosis of gastric cancer patients.

Entities:  

Year:  2010        PMID: 21969138      PMCID: PMC3180103     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  39 in total

Review 1.  Epigenetic field for cancerization.

Authors:  Toshikazu Ushijima
Journal:  J Biochem Mol Biol       Date:  2007-03-31

2.  The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer.

Authors:  Laszlo Radvanyi; Devender Singh-Sandhu; Scott Gallichan; Corey Lovitt; Artur Pedyczak; Gustavo Mallo; Kurt Gish; Kevin Kwok; Wedad Hanna; Judith Zubovits; Jane Armes; Deon Venter; Jalil Hakimi; Jean Shortreed; Melinda Donovan; Mark Parrington; Pamela Dunn; Ray Oomen; James Tartaglia; Neil L Berinstein
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-25       Impact factor: 11.205

3.  Mutation of the mouse klotho gene leads to a syndrome resembling ageing.

Authors:  M Kuro-o; Y Matsumura; H Aizawa; H Kawaguchi; T Suga; T Utsugi; Y Ohyama; M Kurabayashi; T Kaname; E Kume; H Iwasaki; A Iida; T Shiraki-Iida; S Nishikawa; R Nagai; Y I Nabeshima
Journal:  Nature       Date:  1997-11-06       Impact factor: 49.962

4.  IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.

Authors:  I Ibanez de Caceres; M Cortes-Sempere; C Moratilla; R Machado-Pinilla; V Rodriguez-Fanjul; C Manguán-García; P Cejas; F López-Ríos; L Paz-Ares; J de CastroCarpeño; M Nistal; C Belda-Iniesta; R Perona
Journal:  Oncogene       Date:  2009-12-21       Impact factor: 9.867

5.  Methylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer.

Authors:  A Wiley; D Katsaros; S Fracchioli; H Yu
Journal:  Int J Gynecol Cancer       Date:  2006 Jan-Feb       Impact factor: 3.437

Review 6.  Deciphering the underlying genetic and epigenetic events leading to gastric carcinogenesis.

Authors:  Paraskevi Vogiatzi; Carla Vindigni; Franco Roviello; Alessandra Renieri; Antonio Giordano
Journal:  J Cell Physiol       Date:  2007-05       Impact factor: 6.384

7.  Aberrant promoter methylation of insulin-like growth factor binding protein-3 gene in human cancers.

Authors:  Kunitoshi Tomii; Kazunori Tsukuda; Shinichi Toyooka; Hideaki Dote; Tadashi Hanafusa; Hiroaki Asano; Minoru Naitou; Hiroyoshi Doihara; Takumi Kisimoto; Hideki Katayama; Harvery I Pass; Hiroshi Date; Nobuyoshi Shimizu
Journal:  Int J Cancer       Date:  2007-02-01       Impact factor: 7.396

8.  Warburg effect revisited: an epigenetic link between glycolysis and gastric carcinogenesis.

Authors:  X Liu; X Wang; J Zhang; E K Y Lam; V Y Shin; A S L Cheng; J Yu; F K L Chan; J J Y Sung; H C Jin
Journal:  Oncogene       Date:  2009-11-02       Impact factor: 9.867

9.  Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts.

Authors:  Yudi Pawitan; Judith Bjöhle; Lukas Amler; Anna-Lena Borg; Suzanne Egyhazi; Per Hall; Xia Han; Lars Holmberg; Fei Huang; Sigrid Klaar; Edison T Liu; Lance Miller; Hans Nordgren; Alexander Ploner; Kerstin Sandelin; Peter M Shaw; Johanna Smeds; Lambert Skoog; Sara Wedrén; Jonas Bergh
Journal:  Breast Cancer Res       Date:  2005-10-03       Impact factor: 6.466

10.  Fibulin 1 is downregulated through promoter hypermethylation in gastric cancer.

Authors:  Y Y Cheng; H Jin; X Liu; J M T Siu; Y P Wong; E K O Ng; J Yu; W-K Leung; J J Y Sung; F K L Chan
Journal:  Br J Cancer       Date:  2008-11-04       Impact factor: 7.640

View more
  41 in total

1.  Homeobox D10 gene, a candidate tumor suppressor, is downregulated through promoter hypermethylation and associated with gastric carcinogenesis.

Authors:  Liangjing Wang; Shujie Chen; Meng Xue; Jing Zhong; Xian Wang; Lihong Gan; Emily K Y Lam; Xin Liu; Jianbin Zhang; Tianhua Zhou; Jun Yu; Hongchuan Jin; Jianmin Si
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

2.  Promoter methylation confers kidney-specific expression of the Klotho gene.

Authors:  Masahiro Azuma; Daisuke Koyama; Jiro Kikuchi; Hiromichi Yoshizawa; Dissayabutra Thasinas; Kazuhiro Shiizaki; Makoto Kuro-o; Yusuke Furukawa; Eiji Kusano
Journal:  FASEB J       Date:  2012-07-10       Impact factor: 5.191

3.  Epigenetic reactivation of p21CIP1/WAF1 and KLOTHO by a combination of bioactive dietary supplements is partially ERα-dependent in ERα-negative human breast cancer cells.

Authors:  Sonam Sinha; Samriddhi Shukla; Sajid Khan; Trygve O Tollefsbol; Syed M Meeran
Journal:  Mol Cell Endocrinol       Date:  2015-02-25       Impact factor: 4.102

4.  MicroRNA-339 and microRNA-556 regulate Klotho expression in vitro.

Authors:  Stephen J Mehi; Astha Maltare; Carmela R Abraham; Gwendalyn D King
Journal:  Age (Dordr)       Date:  2013-07-02

5.  Changes in Biomarker Profile and Left Ventricular Hypertrophy Regression: Results from the Frequent Hemodialysis Network Trials.

Authors:  Christopher T Chan; George A Kaysen; Gerald J Beck; Minwei Li; Joan Lo; Michael V Rocco; Alan S Kliger
Journal:  Am J Nephrol       Date:  2018-04-05       Impact factor: 3.754

6.  Frequent methylation of the KLOTHO gene and overexpression of the FGFR4 receptor in invasive ductal carcinoma of the breast.

Authors:  Ashraf Dallol; Abdelbaset Buhmeida; Adnan Merdad; Jaudah Al-Maghrabi; Mamdooh A Gari; Muhammad M Abu-Elmagd; Aisha Elaimi; Mourad Assidi; Adeel G Chaudhary; Adel M Abuzenadah; Taoufik Nedjadi; Eramah Ermiah; Shadi S Alkhayyat; Mohammed H Al-Qahtani
Journal:  Tumour Biol       Date:  2015-07-08

7.  Klotho suppresses colorectal cancer through modulation of the unfolded protein response.

Authors:  Tammi Arbel Rubinstein; Shiri Shahmoon; Ehud Zigmond; Tal Etan; Keren Merenbakh-Lamin; Metsada Pasmanik-Chor; Gil Har-Zahav; Iris Barshack; Gilad W Vainer; Nir Skalka; Rina Rosin-Arbesfeld; Chen Varol; Tami Rubinek; Ido Wolf
Journal:  Oncogene       Date:  2018-09-19       Impact factor: 9.867

8.  The anti-aging and tumor suppressor protein Klotho enhances differentiation of a human oligodendrocytic hybrid cell line.

Authors:  Ci-Di Chen; Hu Li; Jennifer Liang; Kathryn Hixson; Ella Zeldich; Carmela R Abraham
Journal:  J Mol Neurosci       Date:  2014-06-08       Impact factor: 3.444

Review 9.  Klotho acts as a tumor suppressor in cancers.

Authors:  Biao Xie; Jinhui Chen; Bin Liu; Junkun Zhan
Journal:  Pathol Oncol Res       Date:  2013-07-05       Impact factor: 3.201

Review 10.  Klotho: a novel biomarker for cancer.

Authors:  Xiangxiang Zhou; Xin Wang
Journal:  J Cancer Res Clin Oncol       Date:  2014-08-03       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.